The Outcome of Postoperative Radiation Therapy for Patients with Stage II Pancreatic Cancer (T3 or N1 Disease)

2기(T3 또는 N1) 췌장암 환자들의 수술 후 방사선치료의 성적 및 고찰

  • Kim, Sang-Won (Departments of Radiation Oncology, Ajou University School of Medicine) ;
  • Kim, Myung-Wook (Departments of Surgery, Ajou University School of Medicine) ;
  • Kim, Wook-Hwan (Departments of Surgery, Ajou University School of Medicine) ;
  • Kang, Seok-Yun (Departments of Internal Medicine, Ajou University School of Medicine) ;
  • Kang, Seung-Hee (Departments of Radiation Oncology, Ajou University School of Medicine) ;
  • Oh, Young-Taek (Departments of Radiation Oncology, Ajou University School of Medicine) ;
  • Lee, Sun-Young (Departments of Radiation Oncology, Ajou University School of Medicine) ;
  • Yang, Ju-No (Departments of Radiation Oncology, Ajou University School of Medicine) ;
  • Chun, Mi-Sun (Departments of Radiation Oncology, Ajou University School of Medicine)
  • 김상원 (아주대학교 의과대학 방사선종양학교실) ;
  • 김명욱 (아주대학교 의과대학 외과학교실) ;
  • 김욱환 (아주대학교 의과대학 외과학교실) ;
  • 강석윤 (아주대학교 의과대학 내과학교실) ;
  • 강승희 (아주대학교 의과대학 방사선종양학교실) ;
  • 오영택 (아주대학교 의과대학 방사선종양학교실) ;
  • 이선영 (아주대학교 의과대학 방사선종양학교실) ;
  • 양주노 (아주대학교 의과대학 방사선종양학교실) ;
  • 전미선 (아주대학교 의과대학 방사선종양학교실)
  • Published : 2007.12.30

Abstract

Purpose: To analyze retrospectively the outcome of postoperative radiation therapy with or without concurrent chemotherapy for curatively resected stage II pancreatic cancer with T3 or N1 disease. Materials and Methods: Between January 1996 and December 2005, twenty-eight patients completed adjuvant radiation therapy at Ajou University Hospital. The patients had either pathologic T3 stage or N1 stage. The radiation target volume encompassed the initial tumor bed identified preoperatively, resection margin area and celiac nodal area. In the case of N1 patients, the radiation field extended to the lower margin of the L3 vertebra for covering both para-aortic lymph nodes bearing area. The median total radiation dose was 50 Gy. Ten patients received concurrent chemotherapy. Results: Thirteen patients (46%) showed loco-regional recurrences. The celiac axis nodal area was the most frequent site (4 patients). Five patients showed both loco-regional recurrence and a distant metastasis. Patients with positive lymph nodes had a relatively high probability of a distant metastasis (57.1%). Patients that had a positive resection margin showed a relatively high local failure rate (57.1%). The median disease-free survival period of all patients was 6 months and the 1-and 2-year disease free survival rates were 27.4% and 8.2%, respectively. The median overall survival period was 9 months. The 2-and 3-year overall survival rates were 31.6% and 15.8%, respectively. Conclusion: The pancreatic cancer patients with stage II had a high risk of local failure and a high risk of a distant metastasis. We suggest the concurrent use of an effective radiation-sensitizing chemotherapeutic drug and adjuvant chemotherapy after postoperative radiation therapy for the treatment of patients with stage II pancreatic cancer.

목적: 근치적 절제술을 받고 AJCC 병기 2기(T3또는 N1)로 진단된 췌장암 환자들 중 수술 후 방사선치료를 받은 이들을 대상으로 국소 제어율 및 생존율을 분석하고자 한다. 대상 및 방법: 1996년 1월부터 2005년 12월까지 수술 후 보조적 요법으로 방사선치료 단독 내지는 동시 항암화학 방사선치료를 받은 28명의 환자들의 기록을 후향적으로 분석하였다. 모든 환자들에게서 병리 소견상 췌장 주변 조직으로의 침윤이 있거나 체장 주변 또는 후복강 내 대동맥 주변 임파절 전이가 확인되었다. 방사선치료는 수술 전 영상학적인 자료에서 침범된 종양의 위치 및 수술 변연 부위를 중심으로 $40{\sim}57.6$ Gy (중앙값 50 Gy)를 조사하였으며 병리 소견상 주변 임파절 전이가 확인된 경우엔 제 3 요추부위까지의 대동맥 주변 임파절 부위도 조사야에 포함시켰다. 동시 항암화학요법은 10명의 환자들에게서 병용되었다. 결 과: 최초의 실패 양상이 국소 재발이었던 환자는 13명(46%)였으며 이들 중에서 원격 전이가 같이 동반된 환자는 5명이었다. 호발 부위는 복강축(4명)과 대동맥 주변 임파절 부위였다. 또한 원격 전이가 최초의 실패 양상으로 나타난 환자는 국소재발이 동반된 환자들을 포함하여 72명이었다. 원격전이가 가장 흔히 나타난 곳은 간(10명)이었으며 복강전이, 폐전이 순이었다 임파절 전이가 있는 환자들은 없는 환자에 비해 원격 전이의 가능성이 높았다. (57.1%). 수술 변연 부위에 종양이 남아있는 환자들은 없는 환자들보다 국소 재발의 가능성이 높았다(57.1%). 전체 환자들의 무병 생존기간의 중앙값은 6개월이었으며 1년 및 2년 무병생존율은 각각 27.4%와8.2%였다. 전체 생존기간의 중앙값은 11개월이었고 2년, 3년 생존율은 31.5%, 15.8%였다. 결 론: 2기 췌장암 환자들은 국소 재발 및 원격 전이의 가능성이 높은 고위험군으로 국소 제어율 및 전체 생존율의 향상을 위해서 수술 후 효과적인 방사선치료의 적극적인 시행 및 이후의 보조적인 전신 항암화학요법을 권고하여 시행하는 것이 바람직하다.

Keywords

References

  1. National Statistics Office, Republic of Korea. 2005 Annual report of the cause of death statstics. 2006
  2. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7
  3. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas‐616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;6:567‐579
  4. Kuhlmann KF, de Castro SM, Wesseling JG, et al. Surgical treatment of pancreatic adenocarcinoma; actuarial survival and prognostic factors in 343 patients. Eur J Cancer 2004;40:549‐558 https://doi.org/10.1016/j.ejca.2003.10.026
  5. Westerdahl J, Andren‐Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer‐local or hepatic? Hepatogastroenterology 1993;40:384‐387
  6. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899‐903
  7. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59:2006‐2010
  8. Kim K, Kim S, Chie EK, Kim SW, Bang YJ, Ha SW. Postoperative chemoradiotherapy of pancreatic cancer: What is the appropriate target volume of radiation therapy? Tumori 2005;91:493‐497
  9. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single0institution experience. Ann Surg 1997;225:621‐633
  10. Foo ML, Gunderson LL, Nagorney DM, et al. Pantterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil. Int J Radiat Oncol Biol Phys 1993;26:483‐489
  11. Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiation and chemotherapy for pancreatic adenocarcinoma: the Mayo clinic experience. 2007 Gastrointestinal cancers symposium
  12. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210 https://doi.org/10.1056/NEJMoa032295
  13. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5‐fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776‐784
  14. Abrams RA, Grochow LB, Chakaravarthy A, et al. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observation regarding patterns of failure, radiotherapy dose and CA19‐9 levels. Int J Radiat Oncol Biol Phys 1999;44:1039‐1046
  15. Bakkevold KE, Arnesjo B, Dahl O, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-Results of a controlled, prospective, randomized multicentre study. Eur J Cancer 1993;29A:698‐703
  16. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter, prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685‐1695
  17. Van Laethem JL, Demols A, Gay F, et al. Postoperative adjuvant gemcitabine and concurrent radiation therapy after curative resection of pancreatic head carcinoma: a phase II study. Int J Radiat Biol Phys 2003;56:974-980 https://doi.org/10.1016/S0360-3016(03)00164-0
  18. Demols A, Peters M, Polus M, et al. Adjuvant gemcitabine and concurrent continuous radiation therapy (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian phase II study. Int J Radiat Biol Phys 2005;62:1351-1356 https://doi.org/10.1016/j.ijrobp.2005.01.043
  19. Blackstock AW, Mornex F, Partensky C, et al. Adjuvant Gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer 2006;95:260-265 https://doi.org/10.1038/sj.bjc.6603270
  20. Regine WF, Winter KW, Abrams R, et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5‐FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol (Meeting Abstracts) 2006;24: 4007